Antibody–Drug Conjugates as an Emerging Therapy in Oncodermatology - INRAE - Institut national de recherche pour l’agriculture, l’alimentation et l’environnement Access content directly
Journal Articles (Review Article) Cancers Year : 2022

Antibody–Drug Conjugates as an Emerging Therapy in Oncodermatology

David Schrama
  • Function : Author
  • PersonId : 1078183
Roland Houben
  • Function : Author
  • PersonId : 1084028
Audrey Desgranges
  • Function : Author
  • PersonId : 1133953
Camille Martin
  • Function : Author
  • PersonId : 1133954
Patricia Berthon
Antoine Touzé


Antibody–drug conjugates (ADCs) are an emerging class of therapeutics, with twelve FDA- and EMA-approved drugs for hematological and solid cancers. Such drugs consist in a monoclonal antibody linked to a cytotoxic agent, allowing a specific cytotoxicity to tumor cells. In recent years, tremendous progress has been observed in therapeutic approaches for advanced skin cancer patients. In this regard, targeted therapies (e.g., kinase inhibitors) or immune checkpoint-blocking antibodies outperformed conventional chemotherapy, with proven benefit to survival. Nevertheless, primary and acquired resistances as well as adverse events remain limitations of these therapies. Therefore, ADCs appear as an emerging therapeutic option in oncodermatology. After providing an overview of ADC design and development, the goal of this article is to review the potential ADC indications in the field of oncodermatology.
Fichier principal
Vignette du fichier
2022_Esnault_cancers_vol-14_art-778.pdf (1.74 Mo) Télécharger le fichier
Origin : Publication funded by an institution

Dates and versions

hal-03660391 , version 1 (05-05-2022)





Clara Esnault, David Schrama, Roland Houben, Serge Guyétant, Audrey Desgranges, et al.. Antibody–Drug Conjugates as an Emerging Therapy in Oncodermatology. Cancers, 2022, 14 (3), 19 p. ⟨10.3390/cancers14030778⟩. ⟨hal-03660391⟩
69 View
246 Download



Gmail Facebook X LinkedIn More